The FBXO31 antibody is a research tool designed to detect and study the FBXO31 protein, a member of the F-box protein family that acts as a substrate-recognition component within the SCF (SKP1-CUL1-F-box) ubiquitin ligase complex. FBXO31 plays critical roles in regulating cell cycle progression, DNA damage response, and tumor suppression. It is particularly noted for its involvement in mediating the degradation of key oncoproteins, such as cyclin D1. thereby controlling G1/S phase transition and maintaining genomic stability. Dysregulation of FBXO31 has been implicated in various cancers, including breast, liver, and lung cancers, where its expression is frequently downregulated.
Antibodies targeting FBXO31 are widely used in molecular and cellular biology research to investigate its expression patterns, subcellular localization, and interactions with signaling pathways. These antibodies enable techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP). Validated FBXO31 antibodies are essential for exploring its tumor-suppressive mechanisms, including its response to genotoxic stress and its role in apoptosis. Additionally, studies have linked FBXO31 to neurological disorders, highlighting its broader biological significance. Researchers rely on high-specificity FBXO31 antibodies to dissect its dual roles in cancer and neurodegeneration, offering insights into potential therapeutic targets.